506427-91-4

Usage

Uses

Used in Pharmaceutical Synthesis:
N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine is used as an intermediate in the synthesis of Desmethyl Cariprazine Hydrochloride (D291365), a derivative of Cariprazine (C183490). Cariprazine is an orally active D2/D3 dopamine receptor antagonist with potential applications in the treatment of various psychiatric disorders.
Used in Antipsychotic Drug Development:
In the pharmaceutical industry, N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine plays a crucial role in the development of antipsychotic drugs. It contributes to the synthesis of Cariprazine, a drug candidate with potential therapeutic effects on schizophrenia, bipolar mania, and depression. N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine's interaction with D2/D3 dopamine receptors is believed to be responsible for its antipsychotic properties.
Used in the Treatment of Schizophrenia:
N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine is used as a component in the development of antipsychotic medications for the treatment of schizophrenia. Its role in the synthesis of Cariprazine, a D2/D3 dopamine receptor antagonist, makes it a valuable compound in the fight against this debilitating mental disorder.
Used in the Treatment of Bipolar Mania:
N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine is also used in the development of drugs for the treatment of bipolar mania. As a part of the synthesis process for Cariprazine, it contributes to the creation of a medication that can help stabilize mood swings and manage the symptoms of this complex mental health condition.
Used in the Treatment of Depression:
N-tert-butoxycarbonyl-4-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylcyclohexylamine is utilized in the synthesis of Cariprazine, which has potential applications in the treatment of depression. By targeting D2/D3 dopamine receptors, the drug candidate may help alleviate the symptoms of this widespread mental health issue.

Upstream product

• 41202-77-1 1-(2,3-dichlorophenyl)piperazine 
• 223131-01-9 tert-butyl ((cis)-4-(hydroxymethyl)cyclohexyl)carbamate 
• 364385-64-8 cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester 
• 62456-15-9 methyl (1s,4s)-4-aminocyclohexane-1-carboxylate 
• 118785-97-0 cis-4-amino-cyclohexanecarboxylic acid hydrochloride 
• 1069120-41-7 ((cis)-4-((tert-butoxycarbonyl)amino)cyclohexyl)methyl methanesulfonate 
• 847417-37-2 tert-butyl ((1s,4s)-4-(2-oxoethyl)cyclohexyl)carbamate 
• 327156-95-6 ((1s,4s)-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetic acid 
• 2093293-77-5 trans (2-(1-[4-(N-(tert-butoxycarbonyl))-amino]-cyclohexyl))ethyl 4-methylbenzenesulfonate 
• 119532-26-2 1-(2,3-dichlorophenyl)piperazine hydrochloride 
• 1313279-47-8 trans-(4-cyanomethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 683269-95-6 N-[trans-4-[[(methylsulfonyl)oxy]methyl]cyclohexyl]carbamic acid tert-butyl ester 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 27960-59-4 trans-4-aminocyclohexanecarboxylic acid hydrochloric acid 

Relevant academic research and scientific papers

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

Medicinal chemistry optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D3/D 2 compound (1) led to a series of new piperazine derivatives having affinity to both dopamine D3/

Nitrogen-containing ring derivative regulator as well as preparation method and application thereof

The invention relates to a nitrogen-containing ring derivative regulator as well as a preparation method and an application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a G-protein coupled receptor modulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

C-N bond formation by consecutive continuous-flow reductions towards a medicinally relevant piperazine derivative

A new, continuous-flow consecutive reduction method was developed for the C-N bond formation in the synthesis of the key intermediate of the antipsychotic drug cariprazine. The two-step procedure consists of a DIBAL-H mediated selective ester reduction conducted in a novel, miniature alternating diameter reactor, followed by reductive amination using catalytic hydrogenation on 5% Pt/C. The connection of the optimized modules was accomplished using an at-line extraction to prevent precipitation of the aluminum salt byproducts.

Preparation method of cariprazine key intermediate

The invention relates to a preparation method of a novel cariprazine key intermediate, namely, trans-4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-cyclohexylamine dihydrochloride. The method comprises the following steps of: a) subjecting trans-2-{1-[4-(N-tert-butyloxycarbonyl)-amino] cyclohexyl}-ethanol and 1-(2,3-dichlorophenyl)piperazine to a condensation reaction to prepare trans-N-tert-butyloxycarbonyl-4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-cyclohexylamine; and b) heating the obtained trans-N-tert-butyloxycarbonyl-4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-cyclohexylamine to a temperature of 40-100 DEG C in a mixture containing aqueous hydrochloric acid/methanol to obtain the trans-N-4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-cyclohexylamine dihydrochloride.

Novel preparation method of cariprazine

The invention belongs to the field of medicinal chemistry, and mainly relates to a preparation method of novel N'-(trans-4-{2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl}cyclohexyl)-N,N-dimethylurea,which is as shown in the specification.

Preparation method of cariprazine

The invention provides a preparation method of cariprazine, which comprises the following steps: reacting trans-N-tert-butyloxycarbonyl-4-(2-(4-(2,3-dichlorophenyl)-piperazine-1-yl)-ethyl)-cyclohexylamine with dimethylamine under the conditions of an orga

New preparation method of capsazine (by machine translation)

The present invention relates to a novel N' - (trans -4 - {2 - [4 - (2,3 -dichlorophenyl) -1 - piperazinyl] ethyl} cyclohexyl) - N, N -piperazine 2 - yl]-ethyl}-cyclohexylamine dihydrochloride monohydrate: c) trans N - {1 - {2,3 - 4 -} [1 - (-1 - 2-dichlorophenyl)-piperaz 3-yl]-ethyl}-cyclohexylamine dihydrochloride (c)-cyclohexyl}-cyclohexylamine dihydrochloride (hereinafter referred to as [-1 -4 - (2 -dichlorophenyl)-piperazinyl-4 -yl] 40 - 100 °C 2 -ethyl}-cyclohexylamine -4 - dihydrochloride 2 - (4 - b 2,3 -): c)-cyclohexyl}-cyclohexyl}-(b) 2 -4 - ethyl}-cyclohexylamine dihydrochloride 4 - (b 4 -) 2,3 - c)-1 - cyclohexyl}-cyclohexylamine dihydrochloride (b)-cyclohexylamine dihydrochloride (c) 4 - 2,3 -1 . Contrary to triphosgene, the PH was adjusted to 8 - 9, and concentrated to isolate N' - (trans -4 - {2 - [4 - (2,3 -dichlorophenyl) -1 - piperazinyl] ethyl} cyclohexyl) - N, N - dimethylurea. (by machine translation)

D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine

Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both Gi/o-bi

Preparation method of cariprazine

The invention provides a preparation method of cariprazine. The preparation method of the cariprazine includes that a trans-2-(trans-4-(3, 3-dimethylureido) cyclohexyl) derivative is enabled to reactwith 1-(2, 3-dichlorophenyl) piperazine or salt thereof in an acid-binding agent reaction condition, and then the cariprazine is generated in a reducing agent reaction condition. The preparation method of the cariprazine is few in a synthetic route, simple in technology and conformable to production requirements.

Cyclohexane amine D3/D2 receptor partial agonist

The invention belongs to the technical field of biomedicine, and particularly relates to a cyclohexane amine D3/D2 receptor partial agonist, and a pharmaceutically acceptable salt, a synthesis methodand use of the cyclohexane amine D3/D2 receptor partial